Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDeininger, M.en
dc.contributor.authorHodgson, J.en
dc.contributor.authorShah, N.en
dc.contributor.authorCortes, J.en
dc.contributor.authorKim, D.en
dc.contributor.authorNicolini, F.en
dc.contributor.authorTalpaz, M.en
dc.contributor.authorBaccarani, M.en
dc.contributor.authorMüller, M.en
dc.contributor.authorLi, J.en
dc.contributor.authorParker, W.en
dc.contributor.authorLustgarten, S.en
dc.contributor.authorClackson, T.en
dc.contributor.authorHaluska, F.en
dc.contributor.authorGuilhot, F.en
dc.contributor.authorKantarjian, H.en
dc.contributor.authorSoverini, S.en
dc.contributor.authorHochhaus, A.en
dc.contributor.authorHughes, T.en
dc.contributor.authorRivera, V.en
dc.contributor.authoret al.en
dc.identifier.citationBlood, 2016; 127(6):703-712en
dc.description.abstractBCR-ABL1 kinase domain mutations can confer resistance to first- and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). In preclinical studies, clinically achievable concentrations of the third-generation BCR-ABL1 TKI ponatinib inhibit T315I and all other single BCR-ABL1 mutants except T315M, which generates a single amino acid exchange, but requires 2 sequential nucleotide exchanges. In addition, certain compound mutants (containing ≥2 mutations in cis) confer resistance. Initial analyses based largely on conventional Sanger sequencing (SS) have suggested that the preclinical relationship between BCR-ABL1 mutation status and ponatinib efficacy is generally recapitulated in patients receiving therapy. Thus far, however, such analyses have been limited by the inability of SS to definitively identify compound mutations or mutations representing less than ~20% of total alleles (referred to as "low-level mutations"), as well as limited patient follow-up. Here we used next-generation sequencing (NGS) to define the baseline BCR-ABL1 mutation status of 267 heavily pretreated chronic phase (CP)-CML patients from the PACE trial, and used SS to identify clonally dominant mutants that may have developed on ponatinib therapy (30.1 months median follow-up). Durable cytogenetic and molecular responses were observed irrespective of baseline mutation status and included patients with compound mutations. No single or compound mutation was identified that consistently conferred primary and/or secondary resistance to ponatinib in CP-CML patients. Ponatinib is effective in CP-CML irrespective of baseline mutation status.en
dc.description.statementofresponsibilityMichael W. Deininger, J. Graeme Hodgson, Neil P. Shah, Jorge E. Cortes, Dong-Wook Kim, Franck E. Nicolini, Moshe Talpaz, Michele Baccarani, Martin C. Müller, Jin Li, Wendy T. Parker, Stephanie Lustgarten, Tim Clackson, Frank G. Haluska, Francois Guilhot, Hagop M. Kantarjian, Simona Soverini, Andreas Hochhaus, Timothy P. Hughes, Victor M. Rivera and Susan Branforden
dc.publisherAmerican Society of Hematologyen
dc.rights© 2016 by The American Society of Hematologyen
dc.subjectLeukemia, Myeloid, Chronic-Phaseen
dc.titleCompound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidHughes, T. [0000-0002-0910-3730]en
dc.identifier.orcidBranford, S. [0000-0002-1964-3626]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.